Zobrazeno 1 - 10
of 138
pro vyhledávání: ''
Autor:
Arja Jukkola-Vuorinen, Anniina Jääskeläinen, Kirsi-Maria Haapasaari, Päivi Auvinen, Ylermi Soini, Peeter Karihtala
Publikováno v:
BMC Cancer
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
BMC Cancer, Vol 18, Iss 1, Pp 1-10 (2018)
Background: The subtype of claudin-low breast cancer can be reliably determined only by gene-expression profiling. Attempts have been made to develop immunohistochemical surrogates, which nearly always focus on membranous claudin expression. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0882fc6ea4b5d717997d116945eea4b4
http://urn.fi/urn:nbn:fi-fe201804196713
http://urn.fi/urn:nbn:fi-fe201804196713
Autor:
Gwyn T. Williams, Carlos Caldas, Mirna Mourtada-Maarabouni, Andrew R. Green, Mark R. Pickard, Ian O. Ellis, Vanessa L. Hedge
Publikováno v:
Breast Cancer Research : BCR
INTRODUCTION: Programmed cell death through apoptosis plays an essential role in the hormone-regulated physiological turnover of mammary tissue. Failure of this active gene-dependent process is central both to the development of breast cancer and to
Publikováno v:
BMC Cancer
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
BMC Cancer, Vol 8, Iss 1, p 153 (2008)
Background A number of protein markers have been investigated as prognostic adjuncts in breast cancer but their translation into clinical practice has been impeded by a lack of appropriate validation. Recently, we showed that BCL2 protein expression
Publikováno v:
BMC Cancer
Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial c
Autor:
Laurence N. Kolonel, Song-Yi Park, Melissa A. Little, Shannon M. Conroy, Gertraud Maskarinec, Ian Pagano
Publikováno v:
Breast Cancer Research : BCR
Introduction Mammographic density, a strong predictor for breast cancer incidence, may also worsen prognosis in women with breast cancer. This prospective analysis explored the effect of prediagnostic mammographic density among 607 breast cancer case
Publikováno v:
Breast Cancer Research : BCR
Breast Cancer Research; 17(1), no 23 (2015)
Breast Cancer Research; 17(1), no 23 (2015)
Introduction Global gene expression analysis of tumor samples has been a valuable tool to subgroup tumors and has the potential to be of prognostic and predictive value. However, tumors are heterogeneous, and homogenates will consist of several diffe
Autor:
Sophia Agelaki, Antonia Kalykaki, A. Xyrafas, Emmanouil Saloustros, Kostas Kalbakis, Galatea Kallergi, Dimitris Mavroudis, Stella Apostolaki, M. Perraki, Vassilis Georgoulias
Publikováno v:
Breast Cancer Research : BCR
Background The detection of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTC) before and/or after adjuvant chemotherapy in patients with operable breast cancer is associated with poor clinical outcome. Reliable prognostic markers for
Autor:
Claire Josse, Vincent Bours, Pierre Frères, Guy Jerusalem, Bouchra Boujemla, Stephane Wenric, Karin Segers, Raphaël Marée, Joëlle Collignon, Meriem Boukerroucha, Sonia ElGuendi
Publikováno v:
BMC Cancer
Background The BRCA1 gene plays a key role in triple negative breast cancers (TNBCs), in which its expression can be lost by multiple mechanisms: germinal mutation followed by deletion of the second allele; negative regulation by promoter methylation
Autor:
Helena Hwang, Brian Z. Ring, Marshall T Schreeder, Nancy Watroba, Robert S. Seitz, Christine Murekeyisoni, Swati Kulkarni, Noel C Estopinal, Douglas T. Ross, David G. Hicks, Thaer Khoury, Rodney A. Beck
Publikováno v:
Breast Cancer Research : BCR
Introduction The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified. Methods A dataset
Autor:
Jan G. Hengstler, Marco Johannes Battista, D. Boehm, Susanne Gebhard, Antje Lebrecht, Marcus Schmidt, Christine Solbach, W. Siggelkow, Heinz Koelbl, Cristina Cadenas, Rosemarie Marchan, Birte Hellwig, Jörg Rahnenführer, Isabel Sicking, M. Gehrmann
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 562 (2012)
BMC Cancer
BMC Cancer
Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Metho